Peptide Atlas · Mineral

Potassium phosphate (injectable)

In a randomized study in critically ill patients with hypophosphatemia, 30 or 45 mmol of intravenous potassium phosphate corrected phosphate by the end of the infusion in 98%, whether given over 2 or 4 hours (moderate) or 3 or 6 hours (severe), with no adverse events.

emerging

provisional
PubChem 24450
1 citation
0 discussions
0 followers
dipotassium hydrogen phosphate (K2HPO4)
monopotassium phosphate (KH2PO4)
potassium phosphate for injection

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 1 citation resolves to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Potassium phosphate (injectable). Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Rapid intravenous potassium phosphate repletion in ICU hypophosphatemia (RCT, n=47)	emerging	pmid 12845429

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.